Roche Holding AG (ROP SW) is a global biopharmaceutical and diagnostics leader headquartered in Basel, Switzerland. Operating through its Pharmaceuticals division (innovative oncology, immunology, ophthalmology, and neurology drugs) and Diagnostics division (in vitro diagnostics, digital pathology, molecular testing), Roche is a pioneer in personalized healthcare and companion diagnostics.

Roche possesses a formidable patent portfolio in oncology and biologics, integrated with a market-leading global diagnostics franchise that creates high switching costs for clinical laboratories. The company is largely past its major legacy patent cliff and maintains strong R&D productivity, aiming to launch up to 19 new molecular entities (NMEs) by 2030 (with peak sales potential exceeding CHF 3 billion each).

• 1H 2026 & Pipeline Momentum (07/23/2026): Reaffirmed 2026 CER guidance. Key growth drivers Hemlibra (outlook raised to mid-single digits) and Vabysmo offset competitive pressure on Ocrevus.
• Regulatory Milestones: FDA granted Priority Review for giredestrant in curative ER+ adjuvant breast cancer (lidERA study, decision expected Nov 30, 2026) and Enspryng in thyroid eye disease (decision Oct 15, 2026). Divarasib demonstrated superior Phase 3 lung cancer survival vs approved KRAS G12 inhibitors.
• U.S. Investment & Policy De-risking: Genentech signed a major Dec 2025 agreement with the U.S. government securing a 3-year tariff exemption in exchange for lower drug prices and a $50B 5-year U.S. capital investment plan (including new obesity drug manufacturing).

• Currency Translation Drag: Foreign exchange volatility remains a key headwind, expected to hit 2026 reported sales by -4% and core EPS by -6%.
• Pipeline Execution & Competition: Clinical trial execution risks across a massive 19-NME portfolio by 2030, particularly in the crowded obesity market (petrelintide).